Results 141 to 150 of about 26,315,175 (213)

A Noncanonical MET Exon 14 Splice-Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib. [PDF]

open access: yesThorac Cancer
Oh HJ   +9 more
europepmc   +1 more source

New Treatment Strategy and Future Research Direction for BRAF-Mutated Cancer. [PDF]

open access: yesCancer Sci
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Takahashi M, Taniguchi SH, Yoshida Y.
europepmc   +2 more sources

Advanced Materials for Biologics Delivery to Brain Tumors

open access: yesAdvanced Materials, Volume 38, Issue 61, 2 November 2026.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng   +4 more
wiley   +1 more source

EBV‐Driven ODC1 Upregulation Enhances Polyamine Anabolism to Promote Viral Replication and Cisplatin Resistance in Nasopharyngeal Carcinoma

open access: yesAdvanced Science, Volume 13, Issue 61, 3 November 2026.
EBV‑BZLF1 initiates ODC1‑driven polyamine anabolism that correlates with poor clinical prognosis in nasopharyngeal carcinoma. The ODC1–spermidine axis promotes viral replication, cell proliferation and innate immune evasion. Pharmacological inhibition of ODC1 rescues cisplatin sensitivity, establishing ODC1 as a viable therapeutic target for EBV ...
Yueshuo Li   +9 more
wiley   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3902-3913, November 2026.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub   +3 more
wiley   +1 more source

Purification of Advanced Therapeutics by Flow‐Through Pseudo‐Affinity Chromatography: Bi‐Specific mABs, Fc Fusion Proteins, and Adeno‐Associated Viruses

open access: yesBiotechnology and Bioengineering, Volume 123, Issue 11, Page 3079-3105, November 2026.
ABSTRACT Modern biopharmaceutical manufacturing requires purification platforms capable of processing structurally and functionally diverse products while addressing the challenge of removing persistent and high‐risk host cell proteins (HCPs).
Wenning Chu   +23 more
wiley   +1 more source

Intratumoural Bacterial Co‐Occurrence is Associated With an Altered Tumour Immune Microenvironment and Poor Prognosis in Colorectal Cancer

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Alterations in the composition of the gut microbiota have been associated with colorectal cancer (CRC), with growing evidence indicating that specific microbes can have an impact on the tumour microenvironment. In this study, we investigated the associations of an oral pathobiont consortium comprising P. stomatis, F. nucleatum sensu lato and P.
Marina Rubio Garcia   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy